{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P00533",
      "entity_text" : "EGFR",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5284616",
      "entity_text" : "rapamycin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Among molecular targeted therapies, ARDS has been best described following agents that inhibit EGFR (gefitinib, erlotinib, cetuximab), the antilymphocyte monoclonal antibodies (rituximab, alemtuzumab, ofatumumab), and the rapamycin inhibitors (everolimus, temsirolimus).",
  "reading_complete" : "2020-07-28T10:32:26Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T10:28:48Z",
  "trigger" : "inhibit",
  "evidence" : [ "inhibit EGFR (gefitinib, erlotinib, cetuximab), the antilymphocyte monoclonal antibodies (rituximab, alemtuzumab, ofatumumab), and the rapamycin" ],
  "pmc_id" : "7123056",
  "score" : 0
}